

# FORM 7

## MONTHLY PROGRESS REPORT

**Name of CNSX Issuer:** Pivotal Therapeutics Inc. (the "Issuer").

**Trading Symbol:** PVO

**Number of Outstanding Listed Securities:** 72,676,117 common shares

**Date:** August 8, 2011

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

### **Report on Business**

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

Over the previous month, the Issuer has continued to work and deliver on the objectives laid out in the business plan. Specifically, the Issuer has announced the grant of incentive stock options, announced the filings of five provisional patent applications, continued to enrol patients into its clinical trial

assessing the effectiveness of its lead product VASCAZEN™ as an aid in the dietary management of Omega-3 deficient cardiovascular disease patients through elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) Omega-3 fatty acids. Additionally, the Issuer announced that pursuant to the terms of certain outstanding share purchase warrants (the "Warrants") issued on November 30, 2010 and February 2, 2011, an Acceleration Event has occurred and the warrants were called.

**2. Provide a general overview and discussion of the activities of management.**

Management has continued to work and deliver on the objectives laid out in the business plan to commercialize VASCAZEN™ and increase shareholder value. Management accelerated the call of the Warrants because the company had met the terms and conditions required under the private placement. As a result, written notice of the Acceleration Event was distributed via a press release on Thursday, July 14th, 2011. The warrants affected by the Acceleration Event relate to a non-brokered private placement, which closed on February 2, 2011. The expiry term of the warrants had been amended to 15 business days following written notice of the Acceleration Event, that is 5:00pm, Eastern Standard Time, on August 5, 2011.

**3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

This item is not applicable to the Issuer for the month of July 2011.

**4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

This item is not applicable to the Issuer for the month of July 2011.

**5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

This item is not applicable to the Issuer for the month of July 2011.

**6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

This item is not applicable to the Issuer for the month of July 2011.

**7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the**

nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

This item is not applicable to the Issuer for the month of July 2011.

**8. Describe the acquisition of new customers or loss of customers.**

This item is not applicable to the Issuer for the month of July 2011.

**9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

This item is not applicable to the Issuer for the month of July 2011.

**10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

The Issuer hired a Marketing Associate to assist with the commercialization of its lead product VASCAZEN™ - a prescription medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating EPA and DHA to levels associated with reduced risk of cardiovascular complications.

**11. Report on any labour disputes and resolutions of those disputes if applicable.**

This item is not applicable to the Issuer.

**12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

This item is not applicable to the Issuer.

**13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

This item is not applicable to the Issuer.

**14. Provide details of any securities issued and options or warrants granted.**

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Common Shares	2,775,000	Exercise of warrants issued during initial financing.	The aggregate proceeds from the exercise of the warrants equals \$693,750. The proceeds will be used for operational purposes.

(1) State aggregate proceeds and intended allocation of proceeds.

**15. Provide details of any loans to or by Related Persons.**

This item is not applicable to the Issuer for the month of July 2011.

**16. Provide details of any changes in directors, officers or committee members.**

This item is not applicable to the Issuer for the month of July 2011.

**17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

None.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 8<sup>th</sup>, 2011

Rachelle MacSweeney  
Name of Director or Senior  
Officer

"Rachelle MacSweeney"  
Signature  
President & Director  
Official Capacity

<b><i>Issuer Details</i></b> <u>Name of Issuer</u>	<u>For Month End</u>	<u>Date of Report</u> (YY/MM/D)
Pivotal Therapeutics Inc.	July 31, 2011	11/08/08
<u>Issuer Address</u>		
81 Zenway Blvd., Unit 10		
<u>City/Province/Postal Code</u>	<u>Issuer Fax No.</u>	<u>Issuer Telephone No.</u>
Woodbridge, Ontario L4H 0S5	(905) 856-2177	(905) 856-9797
<u>Contact Name</u>	<u>Contact Position</u>	<u>Contact Telephone No.</u>
Rachelle MacSweeney	President & Director	(905) 856-9797
<u>Contact Email Address</u>	<u>Web Site Address</u>	
rmacsweeney@pivotaltherapeutics.us	www.pivotaltherapeutics.us	